A New Look at PARP Inhibitors After the PRIMA Trial's Overall Survival Results
In this article
A substantial proportion of ovarian cancer cases are still diagnosed at an advanced stage. For many years, treatment success depended on platinum-based chemotherapy and supportive care. From 2014, PARP inhibitors entered clinical practice. This approach targeting DNA repair defects changed the treatment paradigm by significantly extending progression-free survival (PFS), particularly in BRCA-mutant or Homologous Recombination Deficiency (HRD)-positive tumors.
However, data maturing in recent years show that the “PARP for everyone” era is giving way to biomarker-based patient selection. At this point, a critical distinction sets the PRIMA trial apart: PRIMA is a maintenance treatment trial; its primary endpoint is PFS, and its secondary endpoint is OS. PRIMA was therefore designed to demonstrate PFS and quality-of-life benefits, rather than detect an OS difference . This detail is decisive when interpreting the results and is a methodological fact that challenges the perception that “niraparib underperformed.”
PRIMA's patient population also differs: stage III–IV epithelial ovarian/fallopian tube/primary peritoneal cancer patients were included across the population , not only HRD-positive patients but also HRD-negative cases. Furthermore, the proportion of BRCA-mutant patients was approximately 30% , indicating a more biologically heterogeneous cohort and influencing how benefit is distributed across subgroups.
An important reason why the overall survival (OS) difference appears limited in long-term analyses is that patients in the placebo arm received PARP inhibitors after progression (crossover). Nevertheless, PRIMA demonstrated that PFS gainspersisted and quality-of-life measures could be maintained in the HRD-positive group. In short, the PRIMA results reflect not niraparib's efficacy, but the effects of study design, patient mix, and the post-treatment journey on the OS signal.
In June 2025, the US Food and Drug Administration (FDA), in light of these data, restricted the niraparib indication to HRD-positive tumors. In line with PRIMA's evidence, this decision moves clinical practice toward “the right biomarker → the right patient → the right agent.” This article discusses PRIMA's final findings, the rationale behind the decision, and the current role of PARP inhibitors in clear numerical and clinical terms.
The FDA's June 2025 Decision: Niraparib's Indication Narrowed
The US Food and Drug Administration (FDA), after reviewing the PRIMA trial's final results after more than five years of follow-up, redefined in June 2025 the approved use of niraparib (Zejula) . The updated label (Zejula Prescribing Information — Sections 1.1, 2.1, and 5.1) now specifies that the drug can be used only in a particular biological patient group.
New Indication (as of June 2025)
- Niraparib may be used only in Homologous Recombination Deficiency (HRD)-positive tumors (defined by a BRCA mutation and/or genomic instability).
- The patient must have stage III–IV epithelial ovarian or fallopian tube or primary peritoneal cancer and must have achieved a complete or partial response to first-line platinum-based chemotherapy.
- Non-HRD (BRCA-wild type and genomically stable) patients should not newly start niraparib treatment.
“The final OS analysis of the PRIMA trial did not demonstrate clinical benefit in non-HRD patients. The benefit–risk balance is therefore unfavorable in this population.”
— FDA, Zejula Prescribing Information, June 2025
This decision is viewed not merely as a narrowing of authorization, but as a sign that molecular evidence has become indispensable in oncology patient selection. The “same treatment for everyone” era is thus giving way to treatment based on genetic profile .
The PRIMA Trial: Long-Term Results (Final Analysis)
After more than five years of follow-up, niraparib maintained its progression-free survival (PFS) advantage, while the overall survival (OS) difference did not become statistically significant in the overall population. Subgroup analyses showed the greatest benefit in the HRD-positive population.
| Parameter | Niraparib | Placebo | Result / HR (95% CI) |
|---|---|---|---|
| OS in the overall population | — | — | HR 1.01 (0.84–1.23) |
| HRD-positive OS | — | — | HR 0.95 (0.70–1.29) |
| HRP (proficient) OS | — | — | HR 0.93 (0.69–1.26) |
| 5-year PFS (overall population) | %22 | %12 | Difference favoring Niraparib persists |
| HRD-positive 5-year PFS | %35 | %16 | Strongest, most durable benefit |
| MDS/AML incidence | %2.3 | %1.6 | Total <%2.5; close monitoring recommended |
Clinical implication: While the PFS benefit clearly persists, treatment crossover may contribute to the weakened OS difference: approximately %40–50of placebo-arm patients subsequently received a PARP inhibitor.
SOLO-1, PAOLA-1, and PRIMA: Three Lessons From Three Major Trials
The first three major phase 3 trials of PARP inhibitors defined the treatment's boundaries and the biomarkers that truly make a difference. The table below summarizes the key points.
| Trial | Agent | Patient Group | OS Result | Clinical Lesson |
|---|---|---|---|---|
| SOLO-1 | Olaparib | BRCA-mutant | 45% OS advantage at 7 years | Durable survival advantage |
| PAOLA-1 | Olaparib + Bevacizumab | HRD-positive | OS advantage in HRD-positive patients | Combination synergy demonstrated |
| PRIMA | Niraparib | HRD(+/–) and HRP | No OS difference; PFS maintained | Benefit only in HRD-positive patients |
In summary:
• Olaparibprovides a substantial OS benefit in the BRCA-mutant group.
• Olaparib + Bevacizumabstands out as a powerful combination in a selected HRD-positive group.
• Niraparibappears to have an effect limited to the HRD-positive population.
Clinical and Ethical Aspects of the FDA Decision
The June 2025 FDA update is more than a label change; it creates a new framework of responsibility for clinicians regarding treatment access, patient information, and toxicity management. The decision places biomarker-based selection at the center of clinical practice.
- PARP inhibitors should not be started without HRD testing. Before deciding on treatment, BRCA (germline/somatic) and genomic instability markers should be assessed.
- Non-HRD (BRCA-wild type and genomically stable) patients should not newly start niraparib. Because long-term OS benefit has not been demonstrated in this population, the benefit–risk balance is unfavorable.
- Patients already taking niraparib should be informed. The narrowed indication should be recorded in patient files; clinical response, toxicity, and patient preference should be considered together when reviewing continuation/interruption/dose adjustment options.
- Niraparib remains a clinical option for HRD-positive patients. In this group, where PFS gains are particularly expected, close monitoring for hematologic toxicity and the rare risk of MDS/AML should continue.
Ethical framework: Clinical decisions depend not only on tumor histology but also on the DNA repair deficiency profile . Patients should be clearly told how biomarker status affects treatment selection, and the advantages and disadvantages of alternatives (such as non-PARPi strategies in HRD-negative patients) should be discussed together.
The New Balance: For Whom Are PARP Inhibitors Appropriate Now, and Why?
Long-term OS data and the FDA's 2025 update have repositioned PARP inhibitors as follows.
| Patient Group | Recommended Agent | Level of Evidence | Expected Benefit | Practical Note |
|---|---|---|---|---|
| BRCA-mutant (germline/somatik) | Olaparib, Niraparib (maintenance after a response to 1st-line treatment) | High | Significant OS and PFS gains (durable long-term effect) | Advantage maintained on long follow-up; hematologic monitoring is essential. |
| HRD-positive, BRCA-wild type | Niraparib or Olaparib + Bevacizumab | IIA for Niraparib, IIB for Olaparib | PFS benefit; OS trend in selected subgroups | Biomarker confirmation is essential; select the agent according to toxicity. |
| HRD-negative (genomically stable) | PARP inhibitor not recommended | Low | No OS difference; PFS gain may not be clinically meaningful | Discuss alternative maintenance/monitoring strategies. |
| HRD status uncertain | Priority: HRD/BRCA testing completion | — | Treatment decisions should be based on test results . | Temporary deferral may be considered; patient information is essential. |
Notes: Evidence levels summarize long-term analyses of major phase 3 trials and label updates. All groups require close monitoring with regular complete blood counts for hematologic toxicity and the rare risk of MDS/AML.
International Regulatory Differences: FDA – TİTCK – SGK Comparison
For Niraparib (Zejula), the FDA's June 2025 decisionrestricted use to HRD-positive patients, while in Türkiye neither authorization nor reimbursement conditions fully reflect this narrowing yet. The table below summarizes the differences among these three authorities.
| Area | US (FDA 2025) | Authorization in Türkiye (TİTCK) | Reimbursement in Türkiye (SGK) |
|---|---|---|---|
| 1st-line maintenance | Only in HRD-positive tumors (BRCA-mutant and/or genomically unstable) | HRD testing not required; authorized for all platinum-responsive patients | Coverage for BRCA1/2-positive or platinum-sensitive patients |
| Recurrent maintenance | Restricted to HRD-positive patients | Authorized for BRCA-mutation-positive patients | Reimbursement only for BRCA-mutation-positive cases |
| HRD-negative patients | Do not start new treatment (unfavorable benefit–risk balance) | Remains authorized, but outside clinical recommendations | Not reimbursed |
| Policy status | Authorization narrowed and officially updated | No revision parallel to the FDA yet | A restricted biomarker-based reimbursement structure already exists |
| Clinical reality | HRD testing mandatory; clear patient selection | HRD testing optional but clinically preferred | BRCA testing applied as a reimbursement condition |
Comment: Current authorization in Türkiye is broader than under the FDA decision, but reimbursement already has a biomarker-based restriction. Thus, although an authorization update is expected, clinical practice is effectively following the FDA's approach: niraparib is not started in HRD-negative patients.
Conclusion
PRIMA trial's long-term overall survival results clearly revealed the effects and limitations of PARP inhibitors. Niraparib continues to extend progression-free survival, but the overall survival difference was limited to HRD-positive and BRCA-mutant patients. Consequently, the FDA narrowed the indication in June 2025, requiring biomarker-based treatment.
This decision marks a turning point in modern oncology: not only tumor type but also the status of the DNA repair mechanism is now central to treatment decisions. In the PARP inhibitor era, clinical selectivity has become a scientific and ethical necessity.
In the coming years, the position of PARP inhibitors will be reshaped by combination strategies, identification of non-HRD biomarkers and development of next-generation DNA repair-targeting agents . This process will redefine not only treatment options but also the boundaries of personalized medicine in oncology.
DROZDOGAN Academy Commentary
PRIMAis, by design, a maintenance trial; with PFS as its primary endpoint, and OS as its secondary endpoint. It is therefore methodologically incorrect to question niraparib's efficacy because “the OS difference is weak.” PRIMA's patient population is heterogeneous: advanced-stage (III–IV) cases include both HRD-positive and HRD-negative patients, and the BRCA-mutant proportion is ~30%. In addition, a substantial proportion of the placebo arm received PARP after progression (~40–50%), which diluted the long-term OS signal.
What Do We Learn?
• HRD biomarkers remain central. PFS and quality-of-life gains are particularly substantial and durable in the HRD-positive group.
• “PARP is for the right patient, not everyone.” New PARP treatment should not be started in the HRD-negative population; alternative strategies should be considered.
• An apparently low OS benefit reflects design and crossover effects, rather than weak drug activity. Maintenance design + post-progression PARP use mask the OS difference.
• The BRCA proportion (~30%) and broad inclusion criteria reflect real-world heterogeneity; this distribution should be considered when interpreting subgroups.
Translation into clinical practice: HRD/BRCA testing is a pretreatment priority. In HRD-positive patients, niraparib (or an appropriate combination) is rational with the aim of extending PFS and preserving quality of life ; in HRD-negative patients, PARP should be avoided and alternative maintenance/monitoring strategies discussed. Follow-up should continue regular complete blood counts for hematologic toxicity and the rare MDS/AML risk.
In conclusion, PRIMA shows not that niraparib underperformed, but that its value becomes clear in patients selected with the right biomarker and that study design and post-progression treatment must be considered when interpreting OS. The FDA's June 2025 decision brought this clinical reality into the regulatory framework.
References
- Monk BJ, et al. Annals of Oncology (2024): PRIMA/ENGOT-OV26/GOG-3012 nihai OS sonuçları — 5 yıllık PFS oranları ve çapraz geçiş bilgileri dahil. Open the article
- U.S. FDA. Zejula (niraparib) — Prior Approval Supplement mektubu (18 Haziran 2025): Endikasyonun HRD-pozitif tümörlerle sınırlandırılması. Official letter (PDF)
- U.S. FDA. Zejula (niraparib) — Güncellenmiş ürün bilgisi/etiket (Haziran 2025): İndikasyon, güvenlik ve PRIMA verileri özetleri. Current label (PDF)
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.